Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis
Top Cited Papers
- 17 August 2006
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (7) , 704-712
- https://doi.org/10.1056/nejmct055183
Abstract
Rheumatoid arthritis that was resistant to methotrexate and sulfasalazine developed in a 25-year-old woman who was evaluated for possible treatment with a tumor necrosis factor inhibitor. These agents are effective in some patients who have not had a response to other therapies. They increase the risk of infection, and their long-term efficacy and safety are not established.Keywords
This publication has 44 references indexed in Scilit:
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnnals of the Rheumatic Diseases, 2004
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 2004
- Evolving concepts of rheumatoid arthritisNature, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- The costs of rheumatoid arthritis: an international long-term viewSeminars in Arthritis and Rheumatism, 2000
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- Mortality in the rheumatic diseasesArthritis & Rheumatism, 1995